CSL Limited (CSL) is a biopharmaceutical company.
CSL researches, develops, manufactures and markets products to treat and prevent human medical conditions.
These conditions include coagulation disorders, viral and bacterial diseases, bleeding disorders and other diseases.
The operational businesses include CSL Behring and bioCSL.
CSL has manufacturing operations in the United States, Germany, Switzerland and Australia.
CSL announced better than expected fiscal 2014 revenues of USD 5.5 billion.
Net earnings after tax, or NPAT, of USD 1.3 billion, both an increase of 8% compared with the prior year. Or 9% and 8% respectively in constant currency terms.
There was a 4% sales decline in bioCSL, the company’s vaccine business and in haemophilia products.
All other categories made solid gains.
Immonuglobulins, or IG drove top-line revenue, which grew by 12% year on year in constant currency terms.
Cash from operations for fiscal 2014 was USD 1.4 billion.
The balance sheet remains solid with cash on hand as at 30 June 2014 of USD 609 million, and net debt to fiscal 2014 EBITDA of 0.7 times.
The share price has jumped from $64 to $71 on the back of the results 10.9% gain this week.
At these prices the company is looking fully valued.
It is currently paying a gross dividend of 1.76% and is one to continue to hold.
For more information about CSL Limited (CSL) please contact us on 07 4771 4577.